Differential pharmacological behaviour of p38 inhibitors in regulating the LPS-induced TNF-α production in human and rat whole blood in vitro

Inflammation

Volumn 34, Issue 2, 2011, Pages 119-132

  Pont Giralt, Mercè ^a   Godessart, Núria ^a   Balagué, Cristina ^a  

^a R and D Centre ^*  (Spain)

Author keywords

LPS; MAPK; TNF ; Whole blood assay

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; DEXAMETHASONE; DORAMAPIMOD; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; ROFLUMILAST; SD 006; TALMAPIMOD; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; IC 50; IN VITRO STUDY; MALE; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; RAT; SPECIES DIFFERENCE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BUTADIENES; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; LIPOPOLYSACCHARIDES; MALE; MONOCYTES; NITRILES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 79956015064     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-010-9215-2     Document Type: Article

References (41)

1. Kumar, S., J. Boehm, and J.C. Lee. 2003. P38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2: 717-726. (Pubitemid 37361787)
2. New, L., and J. Han. 1998. The p38 MAP kinase pathway and its biological function. Trends Cardiovasc Med 8: 220-228. (Pubitemid 28345826)
3. Zhu, W., J.S. Downey, Y. Gu, F. Di Pavona, H. Gram, and J. Han. 2000. Regulation of TNF-α expression in multiple mitogen-activated protein kinases pathways. J Immunol 164: 6349-6358. (Pubitemid 30408816)
4. Brook, M., G. Sully, A.R. Clark, and J. Saklatvala. 2000. Regulation of tumour necrosis factor α mRNA stability by the mitogen-activated protein kinase p38 signalling cascade. FEBS Lett 483: 57-61.
5. Kollias, G., E. Douni, G. Kassiotis, and D. Kontoyiannis. 1999. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 169: 175-194. (Pubitemid 29338732)
6. Toussirot, E., and D. Wendling. 2004. The use of TNFα blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother 5: 581-594. (Pubitemid 38344313)
7. Zhou, F.H., B.K. Foster, X.F. Zhou, A.J. Cowin, and C.J. Xian. 2006. TNF-α mediates p38 MAP kinase activation and negatively regulates bone formation in the injured growth plate in rats. J Bone Miner Res 21: 1075-1088. (Pubitemid 43962836)
8. O'Neill, L.A.J. 2006. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat Rev Drug Discov 5: 549-563. (Pubitemid 43971190)
9. Balagué, C., S. Kunkel, and N. Godessart. 2009. Understanding autoimmune disease: new targets for drug discovery. Drug Discov Today 14: 926-934.
10. Lee, M.R., and C. Dominguez. 2005. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38α protein. Curr Med Chem 12: 2979-2994. (Pubitemid 41672487)
11. Ray, C.A., C. Dumaual, M. Willey, J. Fill, P.J. O'Brien, I. Gourley, et al. 2006. Optimization of analytical and pre-analytical variables associated with an ex vivo cytokine secretion assay. J Pharm Biomed Anal 41: 189-195.
12. Krüger, T., T. Sigsgaard, and E.C. Bonefeld-Jørgensen. 2004. Ex vivo induction of cytokines by mould components in whole blood of atopic and non-atopic volunteers. Cytokine 25: 73-84. (Pubitemid 38018900)
13. Strieter, R.M., D.G. Remick, J.M. Ham, L.M. Colletti, J.P. Lynch 3rd, and S.L. Kunkel. 1990. Tumor necrosis factoralpha gene expression in human whole blood. J Leukoc Biol 47: 336-370.
14. Dominguez, C., D.A. Powers, and N. Tamayo. 2005. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel 8: 421-430. (Pubitemid 40921741)
15. Hatzelmann, A., and C. Schudt. 2001. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297: 267-279. (Pubitemid 32242587)
16. Xu, J.J., B.S. Hendriks, J. Zhao, and D. de Graaf. 2008. Multiple effects of acetaminophen and p38 inhibitors: towards pathway toxicology. FEBS Lett 582: 1276-1282.
17. Ouagued, M., C.A.E. Martin-Chouly, G. Brinchault, C. Leportier-Comoy, A. Depincé, C. Bertrand, et al. 2004. The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-α production in whole blood from COPD patients. Pulm Pharmacol Ther 18: 49-54. (Pubitemid 39647753)
18. Henklova, P., R. Vrzal, B. Papouskova, P. Bednar, P. Jancova, E. Anzenbacherova, et al. 2008. SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes. Eur J Pharmacol 593: 16-23.
19. Kogkopoulou, O., E. Tzakos, G. Mavrothalassitis, C.T. Bladari, F. Paliogianni, H.A. Young, et al. 2006. Conditional up-regulation of IL-2 production by p38 MPAK inactivation is mediated by increased Erk1/2 activity. J Leukoc Biol 79: 1052-1060. (Pubitemid 44835592)
20. Karaman, M.W., S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge, B.T. Campbell, et al. 2008. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132.
21. Bain, J., L. Plater, M. Elliott, N. Shpiro, C.J. Hastie, H. McLauchlan, I. Klevernic, J.S.C. Arthur, D.R. Alessi, and P. Cohen. 2007. The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297-315.
22. Mihara, K., C. Almansa, R.L. Smeets, E.E.M.G. Loomans, J. Dulos, P.M.F. Vink, et al. 2008. A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFα. Br J Pharmacol 154: 153-164. (Pubitemid 351620394)
23. Redl, H., S. Bahrami, G. Schlag, and D.L. Traber. 1993. Clinical detection of LPS and animal models of endotoxemia. Immunobiology 187: 330-345. (Pubitemid 23150776)
24. Van Leeuwen, H.J., M. van der Tol, J.A.G. van Strijp, J. Verhoef, and K.P.M. van Kessel. 2005. The role of tumour necrosis factor in the kinetics of lipopolysaccharide-mediated neutrophil priming in whole blood. Clin Exp Immunol 140: 65-72. (Pubitemid 40461074)
25. Scriba, A., L. Luciano, and B. Steiniger. 1996. High-yield puri.cation of rat monocytes by combined density gradient and immunomagnetic separation. J Immunol Meth 189: 203-216. (Pubitemid 26075747)
26. Strauss-Ayali, D., S.M. Conrad, and D. Mosser. 2007. Monocyte subpopulations and their differentiation patterns during infection. J Leukoc Biol 82: 244-252. (Pubitemid 47230633)
27. Riedemann, N.C., R.-F. Guo, K.D. Bernacki, J.S. Reuben, I.J. Laudes, T.A. Neff, et al. 2003. Regulation by C5a of neutrophil activation during sepsis. Immunity 19: 193-202. (Pubitemid 37011334)
28. Scheinman, R.I., A. Gualberto, C.M. Jewell, J.A. Cidlowski, and A. Baldwin Jr. 1995. Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol Cell Biol 15: 943.
29. Liberman, A.C., J. Drucker, M. Perone, and E. Arzt. 2007. Glucocorticoids in the regulation of transcription factors that control cytokine synthesis. Cytokine Growth Factor Rev 18: 45-56. (Pubitemid 46420547)
30. Deree, J., J.O. Martins, H. Malbostad, W.H. Loomis, and R. Coimbra. 2008. Insights into the regulation of TNF-α production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition. Clinics 63: 321-328.
31. Kwak, H.J., J.S. Song, J.Y. Heo, S.D. Yang, J.Y. Nam, and H.G. Cheon. 2005. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-κB, p38 mitogen-activated protein kinase, and c-jun NH2-terminal kinase activation. J Pharmacol Exp Ther 315: 1188-1195.
32. Riedemann, N.C., R.-F. Guo, T.J. Hollmann, H. Gao, T.A. Neff, J. S. Reuben, et al. 2004. Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis. FASEB J 18: 370-372.
33. Zhang, C., R.A. Baumgartner, K. Yamada, and M.A. Beaven. 1997. Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis factor-α and release of arachidonic acid in mast cells. J Biol Chem 272: 13397-13402. (Pubitemid 27216773)
34. Van den Blink, B., N.P. Juffermans, T. ten Hove, M.J. Schultz, S.J. H. van Deventer, T. van der Poll, et al. 2001. P38 mitogen-ctivated protein kinase inhibition increases cytokine release by macrophages in vitro and during infection in vivo. J Immunol 166: 582-587.
35. Hu, J.-H., T. Chen, Z.H. Zhuang, L. Kong, M.C. Yu, Y. Liu, et al. 2006. Feedback control of MKP-1 expression by p38. Cell Signal 19:393-400.
36. Westermarck, J., S.P. Li, T. Kallunki, J. Han, and V.M. Kähäri. 2001. p38 mitogen-activated protein kinase-dependent activation of protein phosphatases 1 and 2A inhibits MEK1 and MEK2 activity and collagenase 1 (MMP1) gene expression. Mol Cell Biol 21: 2373-2383. (Pubitemid 32222090)
37. Zhao, Q., E.G. Shepherd, M.E. Manson, L.D. Nelin, A. Sorokin, and Y. Liu. 2005. The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide. J Biol Chem 280: 8101-8108.
38. Cheung, P.C.F., D.G. Campbell, A.N. Nebreda, and P. Cohen. 2003. Feedback control of the protein kinase TAK1 by SAPK2a/p38α. EMBO J 22: 5793-5805. (Pubitemid 37408818)
39. Fernández-Martínez, E., M. Morales-Ríos, V. Pérez-Álvarez, and P. Muriel. 2004. Immunomodulatory effects of thalidomide analogs on LPS-induced plasma and hepatic cytokines in the rat. Biochem Pharmacol 68: 1321-1329. (Pubitemid 39179390)
40. Wagner, G., and S. Laufer. 2006. Small molecular anti-cytokine agents. Med Res Rev 26: 1-62. (Pubitemid 43994929)
41. Lumeras, W., F. Caturla, L. Vidal, C. Esteve, C. Balagué, A. Orellana, et al. 2009. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase. J Med Chem 52: 5531-5545.